News headlines about Smith & Nephew (NYSE:SNN) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Smith & Nephew earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 45.7125962667512 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s analysis:
- Smith & Nephew (SNN) Downgraded to “Hold” at Zacks Investment Research (americanbankingnews.com)
- Q2 2019 Earnings Forecast for Smith & Nephew plc Issued By Northcoast Research (SNN) (americanbankingnews.com)
- Jefferies Group Weighs in on Smith & Nephew plc’s FY2018 Earnings (SNN) (americanbankingnews.com)
- Smith & Nephew (SNN) Cut to “Hold” at BidaskClub (americanbankingnews.com)
- Contrasting Sientra (SIEN) & Smith & Nephew (SNN) (americanbankingnews.com)
Smith & Nephew stock traded up $0.19 during trading hours on Tuesday, hitting $38.35. 597,174 shares of the stock were exchanged, compared to its average volume of 788,460. The company has a current ratio of 2.03, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $16,724.57, a price-to-earnings ratio of 20.21, a P/E/G ratio of 2.21 and a beta of 0.62. Smith & Nephew has a 12 month low of $31.77 and a 12 month high of $40.43.
A number of research firms recently weighed in on SNN. Zacks Investment Research cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Tuesday. HSBC raised shares of Smith & Nephew from a “hold” rating to a “buy” rating in a research note on Monday, March 26th. ValuEngine cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. Canaccord Genuity reissued a “buy” rating on shares of Smith & Nephew in a research note on Thursday, February 8th. Finally, JPMorgan Chase raised shares of Smith & Nephew from a “neutral” rating to an “overweight” rating in a research note on Thursday, January 25th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Smith & Nephew presently has an average rating of “Buy” and a consensus target price of $43.50.
TRADEMARK VIOLATION WARNING: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://stocknewstimes.com/2018/04/17/smith-nephew-snn-receiving-somewhat-positive-news-coverage-analysis-finds.html.
Smith & Nephew Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.